Mizetam (Atorvastatin, Ezetimibe)

Atorvastatin, the active ingredient in Mizetam, is a statin and cholesterol absorption inhibitor presented as a fixed‑dose oral tablet for oral use. It lowers elevated blood cholesterol and is indicated for primary hypercholesterolemia, mixed dyslipidemia, and familial hypercholesterolemia in adults.

GNH USA supplies Mizetam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution, ensuring batch traceability and regulatory compliance for each shipment.

Mizetam is used to manage lipid disorders by reducing low‑density lipoprotein cholesterol levels.

- Primary hypercholesterolemia: lowers LDL‑C and total cholesterol, helping achieve target lipid levels in patients with elevated cholesterol. - Mixed dyslipidemia: reduces both LDL‑C and triglycerides while modestly raising HDL‑C, addressing combined lipid abnormalities. - Familial hypercholesterolemia: provides significant LDL‑C reduction in genetically high‑cholesterol patients when diet and lifestyle alone are insufficient.

Adverse reactions may occur with Mizetam and are categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Gastrointestinal discomfort: including nausea, abdominal pain or diarrhea. - Myalgia: muscle aches without weakness. - Elevated liver enzymes: transient increase in ALT/AST. - Fatigue: general tiredness. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Acute liver injury: marked elevation of hepatic enzymes or jaundice. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Pancreatitis: abdominal pain with elevated pancreatic enzymes. - Myopathy with marked CK elevation: muscle weakness with high creatine kinase. - Hepatotoxicity: liver dysfunction requiring discontinuation.

Before prescribing Mizetam, clinicians should consider several safety measures.

- Liver function monitoring: assess baseline ALT/AST and repeat periodically. - Muscle symptom assessment: evaluate any unexplained muscle pain, tenderness or weakness. - Renal function evaluation: adjust use in patients with significant renal impairment. - Contraindication review: avoid in active liver disease or unexplained persistent elevations of hepatic enzymes. - Drug interaction check: review concomitant medications that may increase statin exposure. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mizetam may interact with other medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may markedly increase atorvastatin levels. - Gemfibrozil: significantly raises risk of myopathy and rhabdomyolysis. - Cyclosporine: enhances statin exposure, increasing muscle toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Digoxin: possible increase in serum digoxin concentrations. - Other fibrates (e.g., fenofibrate): may modestly raise risk of muscle-related events. - Antacids containing aluminum or magnesium: may reduce ezetimibe absorption, affecting efficacy.